肽- PROTAC在人癌细胞中诱导的高效PD - 1/PD - L1降解。 - Suppr

Suppr

超能文献

High-potency PD-1/PD-L1 degradation induced by Peptide-PROTAC in human cancer cells.

作者信息

Dai Meng-Yuan, Shi Yu-Ying, Wang An-Jin, Liu Xue-Lian, Liu Miao, Cai Hong-Bing

机构信息

Department of Gynecological Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China.

Hubei Key Laboratory of Tumor Biological Behaviors, Wuhan, China.

出版信息

Cell Death Dis. 2022 Nov 4;13(11):924. doi: 10.1038/s41419-022-05375-7.

DOI:10.1038/s41419-022-05375-7

PMID:36333311

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9636179/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/667b/9636179/6d6ec5f4c89b/41419_2022_5375_Fig1_HTML.jpg

相似文献

High-potency PD-1/PD-L1 degradation induced by Peptide-PROTAC in human cancer cells.肽- PROTAC在人癌细胞中诱导的高效PD - 1/PD - L1降解。

Cell Death Dis. 2022 Nov 4;13(11):924. doi: 10.1038/s41419-022-05375-7.

A cyclic peptide-based PROTAC induces intracellular degradation of palmitoyltransferase and potently decreases PD-L1 expression in human cervical cancer cells.一种基于环状肽的 PROTAC 诱导棕榈酰转移酶的细胞内降解，并显著降低人宫颈癌细胞中 PD-L1 的表达。

Front Immunol. 2023 Oct 2;14:1237964. doi: 10.3389/fimmu.2023.1237964. eCollection 2023.

Effect of the hairpin structure of peptide inhibitors on the blockade of PD-1/PD-L1 axis.肽抑制剂发夹结构对 PD-1/PD-L1 轴阻断的影响。

Biochem Biophys Res Commun. 2020 Jun 25;527(2):453-457. doi: 10.1016/j.bbrc.2020.04.018. Epub 2020 Apr 23.

Design, synthesis and evaluation of PD-L1 peptide antagonists as new anticancer agents for immunotherapy.设计、合成及评估 PD-L1 肽拮抗剂作为癌症免疫治疗的新型药物。

Bioorg Med Chem. 2021 Jan 15;30:115951. doi: 10.1016/j.bmc.2020.115951. Epub 2020 Dec 15.

Discovery of Small-Molecule Inhibitors of the PD-1/PD-L1 Axis That Promote PD-L1 Internalization and Degradation.促进PD-L1内化与降解的PD-1/PD-L1轴小分子抑制剂的发现。

J Med Chem. 2022 Mar 10;65(5):3879-3893. doi: 10.1021/acs.jmedchem.1c01682. Epub 2022 Feb 21.

Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1.骨髓瘤 B7-H1（PD-L1）与 PD-1 结合诱导的骨髓瘤耐药性。

Cancer Immunol Res. 2016 Sep 2;4(9):779-88. doi: 10.1158/2326-6066.CIR-15-0296. Epub 2016 Jul 20.

PD-1 and PD-L1 expression on the prognosis of ovarian cancer.PD-1和PD-L1表达对卵巢癌预后的影响

J Biol Regul Homeost Agents. 2019 Jul-Aug;33(4):1161-1166.

Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer Immunotherapy.泛素化在癌症免疫治疗中调控 PD-1/PD-L1 中的新兴作用。

Mol Ther. 2021 Mar 3;29(3):908-919. doi: 10.1016/j.ymthe.2020.12.032. Epub 2021 Jan 1.

HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity.HIP1R 通过靶向 PD-L1 到溶酶体降解来改变 T 细胞介导的细胞毒性。

Nat Chem Biol. 2019 Jan;15(1):42-50. doi: 10.1038/s41589-018-0161-x. Epub 2018 Nov 5.

Beyond T Cells: Understanding the Role of PD-1/PD-L1 in Tumor-Associated Macrophages.超越 T 细胞：理解 PD-1/PD-L1 在肿瘤相关巨噬细胞中的作用。

J Immunol Res. 2019 Nov 4;2019:1919082. doi: 10.1155/2019/1919082. eCollection 2019.

引用本文的文献

Negative Immune Checkpoint Inhibitors.阴性免疫检查点抑制剂

Pharmaceutics. 2025 May 28;17(6):713. doi: 10.3390/pharmaceutics17060713.

Peptide based vesicles for cancer immunotherapy: design, construction and applications.用于癌症免疫治疗的肽基囊泡：设计、构建与应用

Front Immunol. 2025 May 27;16:1609162. doi: 10.3389/fimmu.2025.1609162. eCollection 2025.

Peptide-Drug Conjugates as Next-Generation Therapeutics: Exploring the Potential and Clinical Progress.肽-药物偶联物作为下一代治疗药物：探索其潜力与临床进展

Bioengineering (Basel). 2025 Apr 30;12(5):481. doi: 10.3390/bioengineering12050481.

Prodrug Approach as a Strategy to Enhance Drug Permeability.前药策略作为增强药物渗透性的一种方法。

Pharmaceuticals (Basel). 2025 Feb 21;18(3):297. doi: 10.3390/ph18030297.

The Impact of Genetic Mutations on the Efficacy of Immunotherapies in Lung Cancer.遗传突变对肺癌免疫疗法疗效的影响。

Int J Mol Sci. 2024 Nov 7;25(22):11954. doi: 10.3390/ijms252211954.

How to target membrane proteins for degradation: Bringing GPCRs into the TPD fold.如何靶向降解膜蛋白：将G蛋白偶联受体纳入靶向蛋白质降解框架

J Biol Chem. 2024 Dec;300(12):107926. doi: 10.1016/j.jbc.2024.107926. Epub 2024 Oct 23.

Treating ICB-resistant cancer by inhibiting PD-L1 via DHHC3 degradation induced by cell penetrating peptide-induced chimera conjugates.通过细胞穿透肽诱导的嵌合体偶联物诱导的 DHHC3 降解来抑制 PD-L1 治疗 ICB 耐药性癌症。

Cell Death Dis. 2024 Sep 30;15(9):701. doi: 10.1038/s41419-024-07073-y.

Biological Activity of Natural and Synthetic Peptides as Anticancer Agents.天然和合成肽作为抗癌剂的生物活性。

Int J Mol Sci. 2024 Jul 1;25(13):7264. doi: 10.3390/ijms25137264.

Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions.靶向蛋白降解（TPD）在免疫治疗中的作用：了解蛋白水解靶向嵌合体（PROTAC）驱动的泛素-蛋白酶体相互作用。

Bioconjug Chem. 2024 Aug 21;35(8):1089-1115. doi: 10.1021/acs.bioconjchem.4c00253. Epub 2024 Jul 11.

Regulation of post-translational modification of PD-L1 and associated opportunities for novel small-molecule therapeutics.PD-L1 翻译后修饰的调控及新型小分子治疗药物的相关机会。

Future Med Chem. 2024 Aug 2;16(15):1583-1599. doi: 10.1080/17568919.2024.2366146. Epub 2024 Jul 1.

本文引用的文献

Targeted protein degradation: mechanisms, strategies and application.靶向蛋白降解：机制、策略与应用。

Signal Transduct Target Ther. 2022 Apr 4;7(1):113. doi: 10.1038/s41392-022-00966-4.

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.通过联合治疗和 PD-L1 调控提高 PD-1/PD-L1 阻断的抗癌疗效。

J Hematol Oncol. 2022 Mar 12;15(1):24. doi: 10.1186/s13045-022-01242-2.

Combination Therapies for HPV-Associated Malignancies.人乳头瘤病毒相关恶性肿瘤的联合治疗

J Clin Cell Immunol. 2021;12(1). Epub 2020 Dec 28.

Peptides that immunoactivate the tumor microenvironment.免疫激活肿瘤微环境的肽。

Biochim Biophys Acta Rev Cancer. 2021 Jan;1875(1):188486. doi: 10.1016/j.bbcan.2020.188486. Epub 2020 Dec 1.

Revisiting the PD-1 pathway.重新审视PD-1通路。

Sci Adv. 2020 Sep 18;6(38). doi: 10.1126/sciadv.abd2712. Print 2020 Sep.

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy.蛋白水解靶向嵌合体（PROTAC）用于靶向蛋白降解和癌症治疗。

J Hematol Oncol. 2020 May 13;13(1):50. doi: 10.1186/s13045-020-00885-3.

Specific Knockdown of α-Synuclein by Peptide-Directed Proteasome Degradation Rescued Its Associated Neurotoxicity.通过肽定向蛋白酶体降解特异性敲低α-突触核蛋白可挽救其相关的神经毒性。

Cell Chem Biol. 2020 Jun 18;27(6):751-762.e4. doi: 10.1016/j.chembiol.2020.03.010. Epub 2020 Apr 30.

Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy.肿瘤细胞内在的 PD-1 受体是一种肿瘤抑制因子，并介导对 PD-1 阻断治疗的耐药性。

Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6640-6650. doi: 10.1073/pnas.1921445117. Epub 2020 Mar 11.

A Comprehensive Review on Current Advances in Peptide Drug Development and Design.关于肽类药物研发与设计的最新进展的全面综述。

Int J Mol Sci. 2019 May 14;20(10):2383. doi: 10.3390/ijms20102383.

Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours.抑制 PD-L1 的棕榈酰化可增强 T 细胞对肿瘤的免疫反应。

Nat Biomed Eng. 2019 Apr;3(4):306-317. doi: 10.1038/s41551-019-0375-6. Epub 2019 Mar 25.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验